Bausch Health Cos (BHC) to Release Earnings on Wednesday

Bausch Health Cos (NYSE:BHC - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data after the market closes on Wednesday, July 30th. Analysts expect the company to announce earnings of $0.93 per share and revenue of $2.47 billion for the quarter.

Bausch Health Cos Stock Down 0.2%

Shares of NYSE BHC traded down $0.02 during trading hours on Friday, reaching $6.77. 754,167 shares of the stock traded hands, compared to its average volume of 1,466,636. The company's 50-day simple moving average is $5.80 and its two-hundred day simple moving average is $6.15. The company has a market capitalization of $2.50 billion, a P/E ratio of -61.50 and a beta of 0.41. Bausch Health Cos has a 52-week low of $4.25 and a 52-week high of $9.85.

Insider Buying and Selling

In other Bausch Health Cos news, Director John Paulson acquired 3,564,059 shares of the firm's stock in a transaction that occurred on Friday, June 13th. The shares were purchased at an average cost of $5.94 per share, for a total transaction of $21,170,510.46. Following the completion of the acquisition, the director owned 32,791,702 shares of the company's stock, valued at approximately $194,782,709.88. The trade was a 12.19% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders purchased 6,352,667 shares of company stock worth $35,870,767. 8.05% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bausch Health Cos

Large investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. increased its stake in Bausch Health Cos by 97.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company's stock valued at $6,136,000 after purchasing an additional 467,270 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Bausch Health Cos by 3.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company's stock worth $2,102,000 after acquiring an additional 9,834 shares during the period. Jones Financial Companies Lllp grew its stake in Bausch Health Cos by 1,548.9% in the 1st quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company's stock worth $162,000 after acquiring an additional 23,451 shares during the period. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Bausch Health Cos in the 1st quarter worth approximately $68,000. Hedge funds and other institutional investors own 78.65% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on BHC shares. Wall Street Zen downgraded Bausch Health Cos from a "buy" rating to a "hold" rating in a report on Saturday, May 10th. Royal Bank Of Canada upped their price objective on Bausch Health Cos from $8.50 to $10.00 and gave the company a "sector perform" rating in a research report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the stock. Based on data from MarketBeat, Bausch Health Cos has a consensus rating of "Hold" and an average target price of $7.38.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.